Abstract
Patients with smouldering or asymptomatic multiple
myeloma (SMM) are not treated until symptomatic disease
develops. SMM is characterised by a serum monoclonal
protein component of 3 g/dL or plasma cell infiltration
into bone marrow of 10% or more.
Original language | English |
---|---|
Pages (from-to) | 240-241 |
Number of pages | 2 |
Journal | Journal of Pharmacy Practice and Research |
Volume | 43 |
Issue number | 3 |
Publication status | Published - 2013 |